Voglio sapere a riguardo di…

47646

Federal Register / Vol. 86, No. 163 / Thursday, August 26, 2021 / Notices
The meeting will take place virtually on October 20, 2021, from 9
a.m. Eastern Time to 6 p.m. Eastern Time.
ADDRESSES: Please note that due to the impact of this COVID19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform.
Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: https www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
Candace Nalls, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5216, Silver Spring, MD 209930002, candace.nalls@
fda.hhs.gov, 3016360510, or FDA
Advisory Committee Information Line, 18007418138 3014430572 in the Washington, DC area. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.
Therefore, you should always check the Agencys website at: https
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the appropriate advisory committee meeting link or call the advisory committee information line to learn about possible modifications before the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On October 20, 2021, the committee will discuss, make recommendations, and vote on information regarding the premarket approval application PMA for the SurgiMend PRS Acellular Bovine Dermal Matrix SurgiMend PRS ABDM
by Integra LifeSciences Corporation.
The proposed Indication for Use, as stated in the PMA, is as follows:
SurgiMend PRS Acellular Bovine Dermal Matrix is intended for use as soft tissue support in post-mastectomy breast reconstruction. SurgiMend PRS
Acellular Bovine Dermal Matrix is specifically indicated for immediate, two-stage, submuscular, alloplastic breast reconstruction.
FDA intends to make background material available to the public no later than 2 business days before the meeting.
If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDAs
jbell on DSKJLSW7X2PROD with NOTICES

DATES:

VerDate Sep<11>2014

17:30 Aug 25, 2021

Jkt 253001

website at the time of the advisory committee meeting, and the background material will be posted on FDAs website after the meeting. Background material and the link to the online teleconference meeting room will be available at https www.fda.gov/
advisory-committees/medical-devicesadvisory-committee/general-and-plasticsurgery-devices-panel. Select the link for the 2021 Meeting Materials. The meeting will include slide presentations with audio components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.
Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. Written submissions may be made to the contact person on or before October 6, 2021.
Oral presentations from the public will be scheduled on October 20, 2021, between approximately 2 p.m. Eastern Time and 3 p.m. Eastern Time. Those individuals interested in making formal oral presentations should notify the contact person see FOR FURTHER
INFORMATION CONTACT. The notification should include a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 28, 2021. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing sessions. The contact person will notify interested persons regarding their request to speak by September 29, 2021.
For press inquiries, please contact the Office of Media Affairs at fdaoma@
fda.hhs.gov or 3017964540.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities.
If you require accommodations due to a disability, please contact Ann Marie Williams at annmarie.williams@
fda.hhs.gov or 3017965966 at least 7
days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at:
https www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
PO 00000

Frm 00033

Fmt 4703

Sfmt 4703

public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory Committee Act 5
U.S.C. app. 2.
Dated: August 20, 2021.
Lauren K. Roth, Acting Principal Associate Commissioner for Policy.
FR Doc. 202118394 Filed 82521; 8:45 am BILLING CODE 416401P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration Docket No. FDA2021N0806

Advisory Committee; Nonprescription Drugs Advisory Committee; Renewal AGENCY:

Food and Drug Administration,
HHS.
Notice; renewal of federal advisory committee.

ACTION:

The Food and Drug Administration FDA or Agency is announcing the renewal of the Nonprescription Drugs Advisory Committee by the Commissioner of Food and Drugs the Commissioner.
The Commissioner has determined that it is in the public interest to renew the Nonprescription Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2023, expiration date.
DATES: Authority for the Nonprescription Drugs Advisory Committee will expire on August 27, 2021, unless the Commissioner formally determines that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT:
Moon Hee V. Choi, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 209930002, 301
8377126, NDAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 1023.65 and approval by the Department of Health and Human Services pursuant to 45 CFR part 11 and by the General Services Administration, FDA is announcing the renewal of the Nonprescription Drugs Advisory Committee the Committee. The Committee is a discretionary Federal advisory committee established to provide advice to the Commissioner.
The Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and SUMMARY:

E:FRFM26AUN1.SGM

26AUN1